Send us your opinions, requests and evaluations.
The restriction imposed by the U.S. Centers for Medicare & Medicaid Services (CMS) in September 2013 regarding the reimbursement for Amyloid PET in dementia and neurodegenerative diseases has been removed. Under the new decision, Medicare administrative contractors will now determine the coverage for Amyloid PET in dementia patients in the U.S.
Send us your opinions, requests and evaluations.